CYP2C19 Genotype Guided DAPT
Phase 3Small molecule
CYP2C19 Genotype Guided DAPT is one of 12 small molecule programs targeting Percutaneous Coronary Intervention. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
11 competitors in Percutaneous Coronary Intervention
#DrugCompanyPhaseTrials
1Plavix
SanofiApproved
Brilinta
AstraZenecaApproved
Bayer Aspirin
BayerApproved
Kengreal
Chiesi Farmaceutici S.p.A.Approved
Aciphex
Akero TherapeuticsApproved
Berberine
XXijing Hospital of Digestive Diseases
Phase 3
N-Acetyl Cyteien
SStanford University
Phase 3
Standard Treatment
Boehringer IngelheimPhase 3
Zastaprazan
YYonsei University
Phase 3
Conventional DAPT
ZZunyi Medical College
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- ZZunyi Medical College